business Today Merck & Co‚ Inc. is one of the most recognizable companies in the pharmaceutical industry. When asked about Merck‚ most people think that it is and always has been a US company. However‚ the company’s history can be traced all the way back to the 1600’s where it was started in Darmstadt‚ Germany. Friedrich Jacob Merck purchased a local store in 1668 where he prepared and sold medicines. The store was called “At the sign of the Angels” and would remain in the Merck family for many
Premium
Guinea and Merck’s Gift to World: A Vaccine for Ebola Christmas may have come early to the West African nation of Guinea; a vaccine developed by Merck and tested on 4‚000 people in Guinea proved 100% effective. Sakoba Keita‚ Ebola response coordinator in Guinea called it Guinea’s gift to the world and it very well might be. Conditions of Testing There are certain medical concerns on the testing methodology. Due to the epidemic nature of the disease and the urgent need for a solution‚ no placebos
Premium Vaccination Vaccine Immune system
UNIVERSITY (MBA – Spring 2011) Strategic Management Case Study Executive Summary: 3 Current Vision 4 Current Mission 4 Values 5 Current Strategies: 6 Developed Vision 7 Developed Mission 7 Reason for new mission 8 SWOT Analysis 9 External opportunities: 9 External Threats: 10 Financial and Operating Performance Analysis 11 Close Competitors 11 Ratio Analysis 11 Key Industry Ratios 14 Operating Profit margin 14 Net Profit
Premium Revenue Financial ratios Generic drug
The New Product Development Process and Merck and Company Introduction The business environment of the 21st century is very different from the business environment 200 years ago. Since the Industrial Revolution until today‚ businesses have developed more and more products to meet the needs of an ever increasing world population. The cycle of business has been changed dramatically since the invention of the Internet‚ which has shortened the selling cycle and made it more convenient
Premium Marketing Product management
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions:
Premium Decision theory Probability theory Decision tree
scientific breakthrough for the pharmaceutical industry and lead to further development of drugs for other diseases. Merck then had to decide if they should abandon the drug altogether as it would be a financial loss or produce it and eliminate the disease and relieve tormented victims. It should be noted that either option chosen would be classified as ethical. There was no law that required Merck to produce the drug although societal backlash would be a consequent. However‚ choosing the alternative of financing
Premium Fortune 500 Fortune 500 Drug
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows
Premium Decision tree Arithmetic mean Variance
Merck & Co.‚ Inc. and GlaxoSmithKline plc October 20‚ 2014 Concepts A. Common Stock i. Authorized – 5‚ 400‚000‚000 shares ii. Common stock issued – 2‚983‚508‚675 shares iii. In 2007‚ Merck issued 2‚983‚508‚675 shares (one cent par value) Total dollar value: 2‚983‚508‚675*0.01=29‚835‚086.75 iv. Common shares held in treasury – 811‚005‚791 v. Common shares outstanding – 2‚172‚502‚884 (shares issued – treasury shares) vi. December 31‚ 2007 market cap - $125‚157‚891‚147
Premium Stock market Stock Generally Accepted Accounting Principles
Merck case analysis Follow this format‚ provide *brief* answers. 1. External (use PESTEL framework) - What are Merck’s opportunities and threats? 2. Internal (use VRIO framework)- what are Merck’s strengths & weaknesses? 3. What is Merck’s performance trend? 4. What strategic actions can Merck take to gain and sustain a competitive advantage in the pharmaceutical industry and why? 1. Merck’s opportunities and threats PESTEL FRAMEWORK - Threats A lot of competition from piers Expiring patents
Premium Pharmacology Generic drug Globalization
Pepcid Case Analysis 1. Why does Merck want to switch Pepcid to OTC status when the patent is good for another six years? How attractive is this opportunity? Over-the-counter market growth is attractive to pharmaceutical companies like P&G who successfully changed Aleve from prescription strength to OTC. Once the patent for Pepcid expires in six years there will inevitably be fierce competition. Since the FDA usually takes so long to process an approval for a prescription-to-OTC switch
Premium Marketing Pharmacology Pharmaceutical drug